11 completed, 5 recruiting, 4 terminated, 3 withdrawn. 28 Phase 2, 3 Phase 3, 2 Phase 1.
Follow Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: new trials by email Literature Review of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating trials Research Report on Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Empasiprubart IV - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) | Phase 2 / Phase 3 | Not yet recruiting | argenx | 6 | 2026-09-01 | 2026-06-10 |
| An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Obinutuzumab β - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β | Phase 1 / Phase 2 | Not yet recruiting | Zhongming Qiu | 24 | 2026-07-15 | 2026-07-10 |
| An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Batoclimab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 26 | 2025-08-28 | 2026-08-11 |
| Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy Rituximab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | University of Kansas Medical Center | 2025-07-01 | 2025-09-17 | |
| A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) TAK-411 - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 2 | Recruiting | Takeda | 36 | 2025-05-14 | 2026-04-23 |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP NVG-2089 - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Nuvig Therapeutics, Inc. | 14 | 2025-04-25 | 2026-10-06 |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 27 | 2025-04-10 | 2026-10-16 |
| Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Imeroprubart, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Recruiting | Immunovant Sciences GmbH | 162 | 2025-03-18 | 2026-09-30 |
| Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immunoadsorption, Immunoglobulins - CIDP | Phase 2 | Recruiting | University of Ulm | 20 | 2023-05-01 | 2026-05-01 |
| To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 94 | 2022-12-15 | 2026-08-11 |
| Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Nipocalimab, Placebo - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 2 / Phase 3 | Recruiting | Janssen Research & Development, LLC | 201 | 2022-09-23 | 2026-09-25 |
| Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) SAR445088 (IV), SAR445088 (SC) - Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2 | Completed | Bioverativ, a Sanofi company | 98 | 2021-04-28 | 2025-10-28 |
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Efgartigimod PH20 SC - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2 | Active not recruiting | argenx | 229 | 2020-09-18 | 2025-06-29 |
| A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) efgartigimod PH20 SC in stage B, placebo in stage B - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 2 | Completed | argenx | 322 | 2020-04-15 | 2024-08-20 |
| A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Rozanolixizumab - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 2 | Completed | UCB Biopharma SRL | 21 | 2019-08-21 | 2022-11-03 |
| A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy Rituximab - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 2 | Unknown | Istituto Clinico Humanitas | 20 | 2019-06-01 | 2023-05-26 |
| The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies Rituximab (genetical recombination), Placebo - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 2 | Completed | Nagoya University | 25 | 2019-03-28 | 2021-08-20 |
| A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Rozanolixizumab, Placebo - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Phase 2 | Completed | UCB Biopharma S.P.R.L. | 34 | 2019-03-26 | 2023-08-01 |
| SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study MD1003 - Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy | Phase 2 | Completed | MedDay Pharmaceuticals SA | 15 | 2016-12-05 | 2020-11-02 |
| Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy H.P. Acthar® Gel - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | Mamatha Pasnoor, MD | 2015-08-01 | 2016-07-18 |
Showing 20 of 28. Sign in to see all of them.
Autoimmune Diseases (3) · Myasthenia Gravis (2) · Neuromyelitis Optica (2) · Autoimmune Diseases of the Nervous System (1) · Charcot-Marie-Tooth Disease (1) · Demyelinating Diseases (1) · Lambert-Eaton Myasthenic Syndrome (1) · Myositis (1) · Opsoclonus-Myoclonus Syndrome (1) · Paraproteinemias (1) · Peripheral Nervous System Diseases (1) · Rasmussen subacute encephalitis (1) · Stiff-Person Syndrome (1) · Vasculitis, Central Nervous System (1)
Chronic Disease (28) · Disease Attributes (28) · Immune System Diseases (28) · Nervous System Diseases (28) · Neuromuscular Diseases (28) · Pathologic Processes (28) · Pathological Conditions, Signs and Symptoms (28) · Polyneuropathies (28) · Polyradiculoneuropathy (28) · Autoimmune Diseases of the Nervous System (27) · Demyelinating Diseases (27) · Peripheral Nervous System Diseases (27) · Autoimmune Diseases (25) · Neurodegenerative Diseases (3) · Cranial Nerve Diseases (2)
Rituximab (3) · rozanolixizumab (2) · Antilymphocyte Serum (1) · Biotin (1) · Carmustine (1) · Cyclophosphamide (1) · Cytarabine (1) · Etoposide (1) · Hematopoietic Stem Cell Transplantation (1) · Immunoglobulins (1) · Immunoglobulins, Intravenous (1) · Injections, Subcutaneous (1) · Interferon beta-1a (1) · Melphalan (1) · Peripheral Blood Stem Cell Transplantation (1)
Immunovant Sciences GmbH (3) · argenx (3) · Biogen (1) · Bioverativ, a Sanofi company (1) · Fred Hutchinson Cancer Center (1) · Istituto Clinico Humanitas (1) · Janssen Research & Development, LLC (1) · Mamatha Pasnoor, MD (1) · MedDay Pharmaceuticals SA (1) · Nagoya University (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Northwestern University (1) · Nuvig Therapeutics, Inc. (1) · Octapharma (1) · Oregon Health and Science University (1)
United States (17) · Germany (10) · Italy (8) · Spain (8) · United Kingdom (8) · Belgium (7) · Denmark (7) · France (7) · Poland (7) · Netherlands (6) · Serbia (6) · Canada (5) · China (5) · Romania (5) · Argentina (4)
Allan Ropper, MD (1) · Frederic Sedel, MD (1) · Jau-Shin Lou, MD, PhD (1) · Johannes Dorst, Prof (1) · Johannes Jakobsen, Dr., MD (1) · Kate Dawson, MD (1) · Leona Holmberg (1) · Mamatha Pasnoor, MD (1) · Masahiro Iijima, Ph. D (1) · Mazen Dimachkie, MD (1) · Qiang Liu, M.D.,Ph.D (1)
PMID 38729747, PMID 12084892, PMID 15703014, PMID 32594300, PMID 37119056, PMID 37899433, PMID 38205888, PMID 38353301, PMID 38729746, PMID 39304241, PMID 42578463
2019 (2), 2016 (1), 2018 (1), 2023 (1), 2025 (1)